Noble Life Science Partners, a division of Noble Financial Capital Markets (Noble) today announced that the company has formed a strategic partnership agreement with Boston-based JSB-Partners (JSB).
JSB is a boutique investment banking firm serving life sciences companies around the world. “We are excited to join forces with JSB, as our fundamental research approach blends perfectly with JSB’s professional culture and passionate team” said Nico Pronk, Noble’s President & CEO. “This relationship is strategic and leverages each other’s respective core competencies. JSB’s strength is in M&A and global drug licensing while ours is in corporate finance, with a 30-year track record of experienced execution. Additionally, JSB’s global reach will position Noble to expand outside of North America” he added.
Sharing resources and working under a common regulatory umbrella is part of the collaboration. “While this aspect of the relationship is attractive”, said Wolfgang Stoiber, MD, MBA, co-founder (1999) and partner of JSB, “it’s the opportunity to cross-leverage our particular skill sets that excites me the most. Both organizations’ clients are the beneficiaries,” he said. “We expect that this collaboration will be of particular interest to all of our clients who are hampered by the lack of enthusiasm of European investors towards life sciences, “added Michel Gouy, MBA, partner of JSB.”Noble is well-positioned to facilitate access to the US financial markets.”
JSB Partners’ singular focus is life sciences companies, while the sector is Noble’s fastest growing research vertical. Broadening the scope of services offered to these companies enhances both the Noble and JSB platforms. “We have developed several strong vehicles to attract emerging growth companies.” said Shawn Titcomb, Noble’s Managing Director & Head of Healthcare Investment and Merchant Banking. “With JSB as partners, our reach expands exponentially particularly when it comes to M&A and drug licensing,” said Titcomb. The vehicles Titcomb refers to include the company’s equity conferences and Noble’s established Scientific Advisory Board (SAB), chaired by Jules Musing the former head of global drug licensing at J&J. “I am very pleased that Noble has taken this step in order to enhance its positioning as a full service investment bank. The SAB is looking forward to collaborating with JSB,” said Musing.
About Noble Financial Capital Markets and Noble LSP (NLSP)
Noble was established in 1984 and is an equity research driven, full-service, investment and merchant banking boutique focused on the healthcare, media & entertainment, technology and natural resources sectors. NLSP was formed in 2014 as a division of Noble. NLSP is a life sciences and investment banking boutique built upon fundamental research and scientific due diligence. The company has offices in New York, Boston, Los Angeles, and Boca Raton. In addition to non-deal road shows and sector-specific conferences (Media Finance and Investor Conference produced in partnership with NAB, and Biox – Biotechnology Symposium) throughout the year, Noble Financial hosts its multi-sector annual (12th in 2016) small-cap investor conference – NobleCon - in January in South Florida. www.nobleconference.com
Members: FINRA, SIPC, MSRB
JSB-Partners offers investment banking and advisory services to biotechnology and pharmaceutical companies. The company specializes in product partnering or licensing arrangements that provide resources and do not dilute the ownership stake held by existing shareholders. The company also engages in merger and acquisition activities that involve purchases, sales and strategic combinations of corporate entities. The company’s headquarters are in Boston, MA.